JP2018538367A - ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 - Google Patents
ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 Download PDFInfo
- Publication number
- JP2018538367A JP2018538367A JP2018545568A JP2018545568A JP2018538367A JP 2018538367 A JP2018538367 A JP 2018538367A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018545568 A JP2018545568 A JP 2018545568A JP 2018538367 A JP2018538367 A JP 2018538367A
- Authority
- JP
- Japan
- Prior art keywords
- alx
- fpr2
- treatment
- receptor
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259498P | 2015-11-24 | 2015-11-24 | |
| US62/259,498 | 2015-11-24 | ||
| PCT/US2016/063036 WO2017091496A1 (en) | 2015-11-24 | 2016-11-21 | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018538367A true JP2018538367A (ja) | 2018-12-27 |
| JP2018538367A5 JP2018538367A5 (enExample) | 2019-12-19 |
Family
ID=57544530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545568A Withdrawn JP2018538367A (ja) | 2015-11-24 | 2016-11-21 | ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180325869A1 (enExample) |
| EP (1) | EP3380091A1 (enExample) |
| JP (1) | JP2018538367A (enExample) |
| KR (1) | KR20180081528A (enExample) |
| CN (1) | CN108348479A (enExample) |
| AU (1) | AU2016359463A1 (enExample) |
| BR (1) | BR112018010155A8 (enExample) |
| CA (1) | CA3006291A1 (enExample) |
| EA (1) | EA201891007A1 (enExample) |
| IL (1) | IL259468A (enExample) |
| MX (1) | MX2018005756A (enExample) |
| SG (1) | SG11201803816RA (enExample) |
| WO (1) | WO2017091496A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034227B1 (ru) | 2015-12-10 | 2020-01-20 | Бристол-Майерс Сквибб Компани | Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1 |
| EP3634958B1 (en) | 2017-06-09 | 2021-07-21 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110996950B (zh) | 2017-06-09 | 2023-04-04 | 百时美施贵宝公司 | 哌啶酮甲酰基肽2受体激动剂和甲酰基肽1受体激动剂 |
| KR102615099B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| SG11202008504SA (en) | 2018-03-05 | 2020-10-29 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| ES2964299T3 (es) | 2018-11-26 | 2024-04-05 | Bristol Myers Squibb Co | Derivados de pirrolidinona como agonistas del receptor del péptido formilado 2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY153985A (en) * | 2007-12-18 | 2015-04-30 | Actelion Pharmaceuticals Ltd | Aminotriazole derivatives as alx agonists |
| CN103221392B (zh) * | 2010-11-17 | 2015-06-03 | 埃科特莱茵药品有限公司 | 桥联螺[2.4]庚酯衍生物 |
| TW201348219A (zh) * | 2012-05-16 | 2013-12-01 | Actelion Pharmaceuticals Ltd | 作爲ａｌｘ受體激動劑之經１－（對－甲苯基）環丙基取代橋聯螺［２．４］庚烷衍生物 |
| EA034227B1 (ru) * | 2015-12-10 | 2020-01-20 | Бристол-Майерс Сквибб Компани | Пиперидиноновые агонисты формилпептидного рецептора 2 и формилпептидного рецептора 1 |
| SG11202008504SA (en) * | 2018-03-05 | 2020-10-29 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
-
2016
- 2016-11-21 CN CN201680068442.7A patent/CN108348479A/zh active Pending
- 2016-11-21 EP EP16810536.9A patent/EP3380091A1/en not_active Withdrawn
- 2016-11-21 CA CA3006291A patent/CA3006291A1/en not_active Abandoned
- 2016-11-21 SG SG11201803816RA patent/SG11201803816RA/en unknown
- 2016-11-21 AU AU2016359463A patent/AU2016359463A1/en not_active Abandoned
- 2016-11-21 WO PCT/US2016/063036 patent/WO2017091496A1/en not_active Ceased
- 2016-11-21 MX MX2018005756A patent/MX2018005756A/es unknown
- 2016-11-21 JP JP2018545568A patent/JP2018538367A/ja not_active Withdrawn
- 2016-11-21 EA EA201891007A patent/EA201891007A1/ru unknown
- 2016-11-21 KR KR1020187014477A patent/KR20180081528A/ko not_active Withdrawn
- 2016-11-21 US US15/776,927 patent/US20180325869A1/en not_active Abandoned
- 2016-11-21 BR BR112018010155A patent/BR112018010155A8/pt not_active Application Discontinuation
-
2018
- 2018-05-17 IL IL259468A patent/IL259468A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201803816RA (en) | 2018-06-28 |
| CN108348479A (zh) | 2018-07-31 |
| BR112018010155A8 (pt) | 2019-02-26 |
| IL259468A (en) | 2018-07-31 |
| BR112018010155A2 (pt) | 2018-11-21 |
| MX2018005756A (es) | 2018-08-01 |
| US20180325869A1 (en) | 2018-11-15 |
| CA3006291A1 (en) | 2017-06-01 |
| KR20180081528A (ko) | 2018-07-16 |
| WO2017091496A1 (en) | 2017-06-01 |
| EP3380091A1 (en) | 2018-10-03 |
| AU2016359463A1 (en) | 2018-07-12 |
| EA201891007A1 (ru) | 2018-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538367A (ja) | ホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）の心臓疾患を治療するための標的設定 | |
| Wang et al. | Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation | |
| Liu et al. | Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| CN107072972B (zh) | 用伊非曲班治疗心脏纤维化的组合物和方法 | |
| JP2021075563A (ja) | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 | |
| KR102354243B1 (ko) | 트롬복산-a2 수용체 길항제를 이용한 근위축증 치료 조성물 및 방법 | |
| KR20140022052A (ko) | 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도 | |
| JP2020520948A (ja) | 心不全の治療用のホルミルペプチド受容体２／リポキシンａ４受容体（ｆｐｒ２／ａｌｘ）アゴニストの新規な使用 | |
| EP3448309A1 (en) | Ifetroban treatment for systemic sclerosis | |
| US10172914B2 (en) | Combination | |
| US20250152671A1 (en) | Medical composition for treating patients exhibiting cardiac decompensation | |
| US20150274751A1 (en) | Treatment of scleroderma using an inhibitor of cbp/catenin | |
| US20230114408A1 (en) | Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists | |
| CN104220083A (zh) | 用于治疗动脉硬化性血管疾病的方法和组合物 | |
| Mommsen et al. | Productive capacity of alveolar macrophages and pulmonary organ damage after femoral fracture and hemorrhage in IL-6 knockout mice | |
| EP4117660B1 (en) | Methods of modulating t-cell activation and treating chronic heart failure using carboranes | |
| JP7233087B2 (ja) | 抗動脈硬化剤 | |
| KR20190013509A (ko) | Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물 | |
| HK40080138A (en) | Methods of modulating t-cell activation using carboranes and carborane analogs | |
| AU2023353716A1 (en) | Compositions and methods for treating graft-related arrhythmia | |
| Ortega et al. | NLRP3 inflammasome as a therapeutic target in cardiovascular diseases: An update of preclinical and clinical evidence | |
| WO2025056188A1 (en) | Relaxin medication | |
| CN116236477A (zh) | 溶血磷脂酸受体5拮抗剂在制备心脏保护药物中的应用 | |
| Van De Sandt et al. | Pharmacological CCR1 blockade limits infarct size, preserves cardiac function and attenuates left ventricular remodeling in a murine model of myocardial ischemia/reperfusion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191106 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20200513 |